ABL
Emilie Chevet has a background in pharmacy and a strong focus on quality assurance. With experience in companies like ABL Europe, Boehringer Ingelheim France, and Delpharm, Emilie has managed projects, handled deviations and change control, and optimized processes in pharmaceutical operations. With a Doctorate in Pharmacy from Faculté de Pharmacie d'Angers and a Master 2 degree in production processes and quality from Université Paul Sabatier Toulouse III, Emilie is skilled in formulation, production, and quality control of pharmaceutical products.
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.